AL-38022A
AL-38022A is a serotonin receptor agonist and psychedelic drug of the indazolethylamine family related to the psychedelic tryptamine 5-MeO-AMT. It is one of a range of similar drugs developed for scientific research and with some possible clinical applications such as in the treatment of glaucoma. The drug acts as a potent and selective agonist for the 5-HT2 family of serotonin receptors, with highest binding affinity for the 5-HT2C subtype and around four times less affinity for 5-HT2A and 5-HT2B. In drug discrimination tests in animals, it fully substituted for the psychedelic drugs 5-MeO-DMT and DOM. AL-38022A was first described in the scientific literature by Richard Glennon and colleagues in 2009.